Time course of reendothelialization of stents in a normal coronary swine model: Characterization and quantification

Veterinary Pathology

Volumn 48, Issue 6, 2011, Pages 1109-1117

  de Prado, A Pérez ^a   Perez Martinez C ^a   Cuellas Ramon C ^a   Gonzalo Orden, J Manuel ^a   Regueiro Purrinos M ^a   Martinez B ^a   Garcia Iglesias M J ^a   Ajenjo, J M ^a   Altonaga J R ^a   Diego Nieto, A ^a   de Miguel, A ^a   Fernandez Vazquez F ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

animal model; coronary stent; endothelialization; percutaneous transluminal coronary angioplasty; scanning electron microscopy

Indexed keywords

ANIMAL; ANIMAL EUTHANASIA; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DRUG ELUTING STENT; ENDOTHELIUM; FOLLOW UP; HUMAN; METABOLISM; METHODOLOGY; RESTENOSIS; SCANNING ELECTRON MICROSCOPY; SWINE; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM; EUTHANASIA, ANIMAL; FOLLOW-UP STUDIES; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; SUS SCROFA; SWINE; THROMBOSIS; TIME FACTORS;

ANIMALIA; SUIDAE;

EID: 80355137086     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985811400446     Document Type: Article

References (52)

1. Alexander EL,Wetzel B.Human lymphocytes: similarity of B and T cell surface morphology.Science. 1975;188:732-734.
2. Bailey S,Seifert P,Huibregtse B,Poff B.Early healing following TAXUS stent implantation: endothelial cell coverage is similar in overlapped TAXUS Express stents and bare metal stents in swine coronary arteries.Cardiovasc Revasc Med. 2006;7:90-92.
3. Bartorelli AL,Trabattoni D,Fabbiocchi F,Montorsi P,de Martini S,Calligaris G,Teruzzi G,Galli S,Ravagnani P.Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent.J Interv Cardiol. 2003;16:499-505.
4. Bertrand ME,Rupprecht HJ,Urban P,Gershlick AH.Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS).Circulation. 2000;102:624-629.
5. Brasselet C,Durand E,Addad F,Vitry F,Chatellier G,Demerens C,Lemitre M,Garnotel R,Urbain D,Bruneval P,Lafont A.Effect of local heating on restenosis and in-stent neointimal hyperplasia in the atherosclerotic rabbit model: a dose-ranging study.Eur Heart J. 2008;29:402-412.
6. Burkhardt E.Scanning electron microscopy of peripheral blood leukocytes of the chickens.Cell Tissue Res. 1979;204:147-153.
7. Camenzind E,Steg PG,Wijns W.Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.Circulation. 2007;115:1440-1455.
8. Chen BX,Ma FY,Wei L,Ruan JH,Xie WL,Zhao XZ,Sun SH,Guo XM,Wang F,Tian T,Chu XW.Neointimal coverage of bare metal and sirolimus-eluting stents evaluated with optical coherence tomography.Heart. 2008;94:566-570.
9. Farb A,Tang AL,Shroff S,Sweet W,Virmani R.Neointimal responses 3 months after (32)P beta-emitting stent placement.Int J Radiat Oncol Biol Phys. 2000;48:889-898.
10. Finn AV,Joner M,Nakazawa G,Kolodgie F,Newell J,John MC,Gold HK,Virmani R.Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.Circulation. 2007;115:2435-2441.
11. Finn AV,Kolodgie FD,Harnek J,Guerrero LJ,Acampado E,Tefera K,Skorija K,Weber DK,Gold HK,Virmani R.Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.Circulation. 2005;112:270-278.
12. Finn AV,Nakazawa G,Joner M,Kolodgie FD,Mont EK,Gold HK,Virmani R.Vascular responses to drug eluting stents: importance of delayed healing.Arterioscler Thromb Vasc Biol. 2007;27:1500-1510.
13. Gunn J,Arnold N,Chan KH,Shepherd L,Cumberland DC,Crossman DC.Coronary artery stretch versus deep injury in the development of in-stent neointima.Heart. 2002;88:401-405.
14. Hamilos MI,Ostojic M,Beleslin B,Sagic D,Mangovski L,Stojkovic S,Nedeljkovic M,Orlic D,Milosavljevic B,Topic D,Karanovic N,Wijns W.Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.J Am Coll Cardiol. 2008;51:2123-2129.
15. Ho S,Clipstone N,Timmermann L,Northrop J,Graef I,Fiorentino D,Nourse J,Crabtree GR.The mechanism of action of cyclosporin A and FK506.Clin Immunol Immunopathol. 1996;80:S40-S45.
16. Hofma SH,van der Giessen WJ,van Dalen BM,Lemos PA,McFadden EP,Sianos G,Ligthart JM,van Essen D,de Feyter PJ,Serruys PW.Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation.Eur Heart J. 2006;27:166-170.
17. Iakovou I,Schmidt T,Bonizzoni E,Ge L,Sangiorgi GM,Stankovic G,Airoldi F,Chieffo A,Montorfano M,Carlino M,Michev I,Corvaja N,Briguori C,Gerckens U,Grube E,Colombo A.Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA. 2005;293:2126-2130.
18. Joner M,Farb A,Cheng Q,Finn AV,Acampado E,Burke AP,Skorija K,Creighton W,Kolodgie FD,Gold HK,Virmani R.Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1.Arterioscler Thromb Vasc Biol. 2007;27:182-189.
19. Joner M,Finn AV,Farb A,Mont EK,Kolodgie FD,Ladich E,Kutys R,Skorija K,Gold HK,Virmani R.Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.J Am Coll Cardiol. 2006;48:193-202.
20. Joner M,Morimoto K,Kasukawa H,Steigerwald K,Merl S,Nakazawa G,John MC,Finn AV,Acampado E,Kolodgie FD,Gold HK,Virmani R.Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma.Arterioscler Thromb Vasc Biol. 2008;28:1960-1966.
21. Joner M,Nakazawa G,Finn AV,Quee SC,Coleman L,Acampado E,Wilson PS,Skorija K,Cheng Q,Xu X,Gold HK,Kolodgie FD,Virmani R.Endothelial cell recovery between comparator polymer-based drug-eluting stents.J Am Coll Cardiol. 2008;52:333-342.
22. Kastrati A,Mehilli J,Pache J,Kaiser C,Valgimigli M,Kelbaek H,Menichelli M,Sabate M,Suttorp MJ,Baumgart D,Seyfarth M,Pfisterer ME,Schomig A.Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.N Engl J Med. 2007;356:1030-1039.
23. Kim JW,Suh SY,Choi CU,Na JO,Kim EJ,Rha S-W,Park CG,Seo HS,Oh DJ.Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent.J Am Coll Cardiol Intv. 2008;1:65-71.
24. Kino T,Hatanaka H,Hashimoto M,Nishiyama M,Goto T,Okuhara M,Kohsaka M,Aoki H,Imanaka H.FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics.J Antibiot (Tokyo). 1987;40:1249-1255.
25. Leon MB,Baim DS,Popma JJ,Gordon PC,Cutlip DE,Ho KK,Giambartolomei A,Diver DJ,Lasorda DM,Williams DO,Pocock SJ,Kuntz RE.A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.N Engl J Med. 1998;339:1665-1671.
26. Matsumoto D,Shite J,Shinke T,Otake H,Tanino Y,Ogasawara D,Sawada T,Paredes OL,Hirata K,Yokoyama M.Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.Eur Heart J. 2007;28:961-967.
27. Nakazawa G,Finn AV,John MC,Kolodgie FD,Virmani R.The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.Am J Cardiol. 2007;100:36M-44M.
28. Nakazawa G,Finn AV,Joner M,Ladich E,Kutys R,Mont EK,Gold HK,Burke AP,Kolodgie FD,Virmani R.Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study.Circulation. 2008;118:1138-1145.
29. Nebeker JR,Virmani R,Bennett CL,Hoffman JM,Samore MH,Alvarez J,Davidson CJ,McKoy JM,Raisch DW,Whisenant BK,Yarnold PR,Belknap SM,West DP,Gage JE,Morse RE,Gligoric G,Davidson L,Feldman MD.Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.J Am Coll Cardiol. 2006;47:175-181.
30. Papadimitriou JM,Finlay-Jones JM,Walters MN.Surface characteristics of macrophages, epithelioid and giant cells using scanning electron microscopy.Exp Cell Res. 1973;76:353-362.
31. Park DW,Park SW,Park KH,Lee BK,Kim YH,Lee CW,Hong MK,Kim JJ,Park SJ.Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.Am J Cardiol. 2006;98:352-356.
32. Pérez de Prado A,Perez Martinez C,Cuellas Ramon C,Gonzalo Orden JM,Altonaga JR,Garcia Iglesias MJ,Regueiro M,Orden MA,Garcia Marin JF,Fernandez-Vazquez F.Endothelialization of nonapposed stent struts located over the origin of a side branch.J Interv Cardiol. 2009;22:222-227.
33. Pérez de Prado A,Pérez-Martínez C,Cuellas-Ramón C,Gonzalo-Orden JM,Regueiro-Purriños M,Martínez-Fernández B,Diego-Nieto A,Fernández-Vázquez F.Analysis of luminal inflammation elicited by different coronary stents in an animal model with scanning electron microscopy.Rev Esp Cardiol. 2011;64:159-162.
34. Perkins LE.Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems.Vet Pathol. 2010;47:58-76.
35. Perkins LE,Chin Quee S,Coleman LA,Lui MJ,Joner M,Virmani R,Acampado E,Kolodgie F.Three in vivo preclinical models to assess re-endothelialization following coronary stent implantation.Am J Cardiol. 2007;100:S176.
36. Pfisterer M,Brunner-La Rocca HP,Buser PT,Rickenbacher P,Hunziker P,Mueller C,Jeger R,Bader F,Osswald S,Kaiser C.Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.J Am Coll Cardiol. 2006;48:2584-2591.
37. Prunotto M,Vignolini C,Lolli V,Black A,Gaggianesi S,Santarelli A,Galloni M.Short-, mid-, and long-term effects of a polymer-free tacrolimus-eluting stent in a porcine coronary model.J Biomed Mater Res A. 2009;88:872-879.
38. Ribichini F,Joner M,Ferrero V,Finn AV,Crimins J,Nakazawa G,Acampado E,Kolodgie FD,Vassanelli C,Virmani R.Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.J Am Coll Cardiol. 2007;50:176-185.
39. Schneider GB.The effects of preparative procedures for scanning electron microscopy on the size of isolated lymphocytes.Am J Anat. 1976;146:93-100.
40. Schwartz RS,Edelman E,Virmani R,Carter A,Granada JF,Kaluza GL,Chronos NAF,Robinson KA,Waksman R,Weinberger J,Wilson GJ,Wilensky RL.Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.Circ Cardiovasc Intervent. 2008;1:143-153.
41. Schwartz RS,Edelman ER,Carter A,Chronos N,Rogers C,Robinson KA,Waksman R,Weinberger J,Wilensky RL,Jensen DN,Zuckerman BD,Virmani R.Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group.Circulation. 2002;106:1867-1873.
42. Schwartz RS,Huber KC,Murphy JG,Edwards WD,Camrud AR,Vlietstra RE,Holmes DR.Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model.J Am Coll Cardiol. 1992;19:267-274.
43. Sheehy A,Murata A,Wallace- Bradley D,Coleman L,Kaluza GL,Perkins L,Kolodgie F,Nakazawa G,Virmani R,Granada JF.Biological evaluation of vascular response to drug eluting stents using optical coherence tomography in a porcine coronary artery model.Am J Cardiol. 2008;102:27i.
44. Shinke T,Li J,Chen JP,Pendyala L,Goodchild T,Jabara R,Geva S,Ueno T,Chronos N,Robinson K,Hou D.High incidence of intramural thrombus after overlapping paclitaxel-eluting stent implantation: angioscopic and histopathologic analysis in porcine coronary arteries.Circ Cardiovasc Intervent. 2008;1:28-35.
45. Spaulding C,Daemen J,Boersma E,Cutlip DE,Serruys PW.A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.N Engl J Med. 2007;356:989-997.
46. St Peter SD,Moss AA,Mulligan DC.Effects of tacrolimus on ischemia-reperfusion injury.Liver Transpl. 2003;9:105-116.
47. Stone GW,Moses JW,Ellis SG,Schofer J,Dawkins KD,Morice MC,Colombo A,Schampaert E,Grube E,Kirtane AJ,Cutlip DE,Fahy M,Pocock SJ,Mehran R,Leon MB.Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.N Engl J Med. 2007;356:998-1008.
48. Virmani R,Guagliumi G,Farb A,Musumeci G,Grieco N,Motta T,Mihalcsik L,Tespili M,Valsecchi O,Kolodgie FD.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?.Circulation. 2004;109:701-705.
49. Virmani R,Kolodgie FD,Farb A,Lafont A.Drug eluting stents: are human and animal studies comparable?.Heart. 2003;89:133-138.
50. Wetzel B,Cannon GB,Alexander EL,Erickson BW,Westbrook EWScanning Electron Microscopy 1974. Johari OCorvin I, ed. Chicago, IL: Illinois Institute of Technology Research Institute; 1974:581-588.
51. Wetzel B,Erickson BW,Levis WRScanning Electron Microscopy 1973. Johari OCorvin I, ed. Chicago, IL: Illinois Institute of Technology Research Institute; 1973:535-542.
52. Wilson GJ,Nakazawa G,Schwartz RS,Huibregtse B,Poff B,Herbst TJ,Baim DS,Virmani R.Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries.Circulation. 2009;120:141-149.